Cargando…

Assessment and monitoring of biologic drug adverse events in patients with psoriasis

BACKGROUND: Current treatment guidelines for biologic therapies in psoriasis differ in their recommendation for the monitoring of adverse events. OBJECTIVE: The aim of this paper was to draw together evidence from the currently available guidelines as a summary of how biologics licensed for the trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanley, Tessa, Handford, Marc, Lavery, Dawn, Yiu, Zenas ZN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683127/ https://www.ncbi.nlm.nih.gov/pubmed/29387593 http://dx.doi.org/10.2147/PTT.S68869

Ejemplares similares

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)

Therapeutic drug monitoring of biologics in psoriasis
por: Liau, MeiQi May, et al.
Publicado: (2019)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis
por: Jabbar-Lopez, Zarif K., et al.
Publicado: (2017)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta‐analysis of randomized controlled trials
por: Rungapiromnan, W., et al.
Publicado: (2017)

Drug repositioning prediction for psoriasis using the adverse event reporting database
por: Ko, Minoh, et al.
Publicado: (2023)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

A review of ocular adverse events of biological anti-TNF drugs
por: Nicolela Susanna, Fernanda, et al.
Publicado: (2020)

Genetics of Psoriasis and Pharmacogenetics of Biological Drugs
por: Prieto-Pérez, Rocío, et al.
Publicado: (2013)

Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
por: Al-Janabi, A, et al.
Publicado: (2022)

Comparative assessment of biologics in treatment of psoriasis: drug design and clinical effectiveness of ustekinumab
por: Garcia-Valladares, Ignacio, et al.
Publicado: (2011)

Psoriasis adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021
por: Learned, Christine, et al.
Publicado: (2022)

Immunogenicity to biological drugs in psoriasis and psoriatic arthritis
por: Valenzuela, Fernando, et al.
Publicado: (2021)

Biological drugs targeting the immune response in the therapy of psoriasis
por: Pastore, Saveria, et al.
Publicado: (2008)

Incidence of Infectious Adverse Events in Patients With Rheumatoid Arthritis and Spondyloarthritis on Biologic Drugs—Data From the Brazilian Registry for Biologics Monitoring
por: Cecconi, Mariana, et al.
Publicado: (2020)

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows
por: Caiazzo, Giuseppina, et al.
Publicado: (2018)

Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
por: Phan, Duc Binh, et al.
Publicado: (2023)

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register
por: Yiu, Zenas Z. N., et al.
Publicado: (2020)

Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
por: Caputo, Valerio, et al.
Publicado: (2021)

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study
por: Mahil, Satveer K., et al.
Publicado: (2021)

Biologics in the management of psoriasis
por: Bahner, Jennifer D, et al.
Publicado: (2009)

Adverse Drug Events Monitoring of Live Attenuated Pandemic Influenza Vaccine
por: Akat, Pramod B, et al.
Publicado: (2011)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
por: Vide, Júlia, et al.
Publicado: (2017)

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
por: Piragine, Eugenia, et al.
Publicado: (2022)

Clinical assessment of immune-related adverse events
por: Sosa, Aaron, et al.
Publicado: (2018)

Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
por: Brown, Joshua D.
Publicado: (2020)

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis
por: Gao, Weiqi, et al.
Publicado: (2023)

5-fluorouracil therapeutic drug monitoring and adverse events in a Romanian population
por: Deac, Andrada-Larisa, et al.
Publicado: (2023)

Adverse Events after Inappropriate In-Home Ultraviolet Phototherapy: Sunburn and Exacerbation of Psoriasis
por: Park, Jong Seo, et al.
Publicado: (2019)

Fibrinogen is Associated with Clinical Adverse Events in Patients with Psoriasis and Coronary Artery Disease
por: Zhao, Lin, et al.
Publicado: (2023)

Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure
por: Mattos, Meghan K., et al.
Publicado: (2019)

Bimekizumab: the new drug in the biologics armamentarium for psoriasis
por: Freitas, Egídio, et al.
Publicado: (2021)

Dose‐Related Adverse Drug Events in Neonates: Recognition and Assessment
por: Allegaert, Karel, et al.
Publicado: (2021)

Imaging techniques in the diagnosis and monitoring of psoriasis
por: Grajdeanu, Ioana-Alina, et al.
Publicado: (2019)

Interrater agreement of two adverse drug reaction causality assessment methods: A randomised comparison of the Liverpool Adverse Drug Reaction Causality Assessment Tool and the World Health Organization-Uppsala Monitoring Centre system
por: Mouton, Johannes P., et al.
Publicado: (2017)

Categorisation of Pharmaceutical Adverse Events Using the Japanese Adverse Drug Event Report Database: Characteristic Adverse Drug Events of the Elderly Treated with Polypharmacy
por: Negishi, Akio, et al.
Publicado: (2020)

Old and New Biological Therapies for Psoriasis
por: Rønholt, Kirsten, et al.
Publicado: (2017)

Pharmacogenetics Update on Biologic Therapy in Psoriasis
por: Muñoz-Aceituno, Ester, et al.
Publicado: (2020)

Biologic Treatments of Psoriasis: An Update for the Clinician
por: Brownstone, Nicholas D, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0u7l1qjj89uq7atv8tlv32cuij